Musculoskeletal Pain Market Snapshot: Amrix is New Player in Field

Cephalon's novel musculoskeletal treatment Amrix appears positioned to give King's Skelaxin a run for the money. For King, however, a possible "at-risk" generic launch in 2009 presents a more immediate threat, analysts say

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet